CriticalSystemic antimycotics. Imidazole derivatives×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
The liver eliminates most quinidine through the enzyme CYP3A4. According to the US quinidine label, quinidine levels rise when ketoconazole is given at the same time, perhaps because of competition for this pathway (quinidine label, US Food and Drug Administration, FDA). Ketoconazole is a strong CYP3A4 inhibitor, and the EU ketoconazole summary of product characteristics (SmPC) lists quinidine among drugs whose plasma levels ketoconazole can raise, with possible QT prolongation (ketoconazole SmPC, European Medicines Agency, EMA). Quinidine prolongs the QT interval in a dose-related way, and high quinidine levels increase the risk of torsade de pointes (quinidine FDA label). Ketoconazole itself may prolong the QT interval. In preclinical studies it inhibited the rapid cardiac delayed rectifier potassium current, and in some clinical studies 200 mg twice daily for 3–7 days increased the corrected QT interval (QTc) by a mean maximum of about 6–12 ms (ketoconazole FDA label).
Symptoms
The main risk is QT prolongation and life-threatening ventricular arrhythmias such as torsade de pointes (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The US ketoconazole label lists feeling faint, lightheaded or dizzy and an irregular or fast heartbeat as possible symptoms of QT prolongation (ketoconazole FDA label). Besides torsade de pointes, quinidine can cause frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation. Excess quinidine causes vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred and double vision, sensitivity to light, headache, confusion and delirium (quinidine FDA label). In quinidine overdose the main dangers are ventricular arrhythmias and low blood pressure (quinidine FDA label).
Management
The combination is contraindicated. The EU ketoconazole summary of product characteristics (SmPC) lists quinidine among contraindicated drugs whose plasma levels ketoconazole can raise, with possible QT prolongation. The US labels for ketoconazole tablets name quinidine in the boxed warning and in the Contraindications section (ketoconazole SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). The interaction table of the US labels says quinidine must not be given with ketoconazole under any circumstances or for up to one week after ketoconazole is stopped (ketoconazole FDA labels). Quinidine is not in the Spanish medicines register. The US quinidine label states that quinidine levels rise with ketoconazole and that other drugs can lead to quinidine toxicity if the quinidine dose is not adjusted appropriately (quinidine FDA label). Ketoconazole is contraindicated in documented congenital or acquired prolongation of the corrected QT interval (QTc). Record an electrocardiogram (ECG) before treatment, within the first week and then as clinically indicated, and monitor the ECG when a QTc-prolonging drug is given at the same time (ketoconazole SmPC, EMA). The contraindication applies to oral ketoconazole. In the European Union its tablets are indicated for endogenous Cushing's syndrome, and doctors experienced in endocrinology or internal medicine start and supervise treatment (EMA). In adults, plasma ketoconazole was undetectable after the cream was applied to the skin or the gel to the scalp, but measurable after the gel was applied to the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Use quinidine with extreme care in long-QT syndromes, after torsade de pointes of any cause, or after marked QTc lengthening in response to quinidine or other drugs. The risk of torsade de pointes rises with bradycardia, low potassium, magnesium or calcium, and high quinidine levels (quinidine FDA label). In haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and correct them as quickly as possible (quinidine FDA label, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ketoconazole tablets (ketoconazole) prescribing information (2025)– FDA, DailyMed setid 6d4be760-c723-4f54-a854-12c61cf91703 (Strides Pharma Science Limited), version 8, revised 12/2025, Boxed Warning, Contraindications, Warnings (incl. QT Prolongation), Precautions: Drug Interactions, Medication Guide
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- AEMPS: Ficha técnica: Ketoconazol Sandoz 20 mg/g gel (nº registro 66037), sección 5.2 (2023)– AEMPS, CIMA, nº registro 66037 (Sandoz), documento 11/2023 (texto revisado 12/2021), secciones 4.5 y 5.2 (niveles plasmáticos detectados tras aplicación en todo el cuerpo)